Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

Cancer

Volumn 88, Issue 5, 2000, Pages 1045-1050

  Miller, Vincent A ^a,b   Ng, Kenneth K ^a   Krug, Lee M ^a   Perez, Wendy ^a   Pizzo, Barbara ^a   Heelan, Robert T ^a   Kris, Mark G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Nonsmall cell lung carcinoma; Vinorelbine

Indexed keywords

CORTICOSTEROID; DOCETAXEL; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; ONYCHOLYSIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FILGRASTIM; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 0034163244     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000301)88:5<1045::AID-CNCR14>3.0.CO;2-J     Document Type: Article

References (22)

1. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968-72.
2. R) in the management of advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997;18(Suppl 2):136.
3. Cortes JE, Pazdur R, Docetaxel. I Clin Oncol 1995:13(10): 2643-55.
4. Miller V, Kris M. Vinorelbine for treatment of advanced non-small cell lung cancer. Med Lett Drugs Ther 1995;37: 72-3.
5. R) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992;28A(II):1863-5.
6. Hino H, Kobayashi K, Hayashihara K, Aoyama A, Shibuya M, Kudo S, et al. In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell lines. Proc Am Assoc Cancer Res 1995;36:299.
7. Aoe K, Ueoka H, Kiura K, Tabata M, Shibayama T, Harada M, et al. Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line. Proc Am Assoc Cancer Res 1996;37:375.
8. Bissery MC, Vrignaud P, Bayssas M, Lavelle F. Preclinical in vivo activity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 1995;14:489.
9. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14(6):1957-60.
10. Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 1994;21(5 [Suppl 10]):21-7.
11. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Handbook for staging of cancer. Philadelphia: J.B. Lippincott Company, 1993.
12. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16(6):2164-8.
13. Krug LM, Kris MG, Grant SC, Heelan RT, Pizzo BA, Perez W, et al. Phase II trial of dose dense docetaxel plus vinorelbine with prophylactic filgrastim (G-CSF) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18: 1775 (abstract).
14. Johnston E, Crawford J, Garst A, Bjurstrom L, Campagna L, Anderson E, et al. Phase I trial of weekly docetaxel (D) and vinorelbine (V) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18:476a.
15. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998;114:1779-81.
16. Ramanathan RK, Belani CP, Reddy VV. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med 1996;124(2):278.
17. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12(2):360-7.
18. Photiou A, Shah P, Leong LK, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 1997;33(3): 463-70.
19. Knick V, Eberwein D, Miller CG. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995;87(14): 1072-7.
20. Baille P, Vernillet L, Vergniol JC, Pasquier O, Bruno R, Azli N, et al. Docetaxel (D) pharmacokinetics (PK): influence of coadministered drugs in phase I combination studies Proc Am Soc Clin Oncol 1998;17:189a.
21. Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, et al. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer 1998;83(10) :2083-90.
22. Haldar S, Basu A, Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.